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Isolated mediastinal skip metastasis
in lung cancer: Is it real N2 disease?
To the Editor:
I read with great interest the study by
Keller and colleagues1 for the Eastern Co-
operative Oncology Group titled “Pro-
longed Survival in Patients With Resected
Non–Small Lung Cancer and Single-Level
N2 Disease,” published in the July 2004
issue of the Journal. The better prognosis
for single-level N2 disease than for multi-
ple N2 station involvement is a relatively
old concept. Keller and colleagues1 cor-
rectly reported that several previous studies
showed a better clinical outcome of pa-
tients with mediastinal skip metastasis than
for patients with metastases also in the hilar
nodes. The results of the Eastern Coopera-
tive Oncology Group’s trial indicated that
this advantage is limited to upper lobe tu-
mors, especially to the left upper lobe. The
authors stated that “the reason for im-
proved survival remains unclear, although
patients with skip metastases may have true
regional disease.”1
I would suggest that the scientific ex-
planation of such results may be found in
the recent studies on the sentinel node in
non–small cell lung cancer. The sentinel
node should be the first site of metastatic
involvement, because it is the first lymph
node that receives afferent lymphatic drain-
age from a primary tumor. The sentinel
lymph node is located in the mediastinum
in as many as 35% of patients; mediastinal
sentinel nodes are generally found from
upper lobe tumors, with the highest inci-
dence in the left upper lobe.2-6 Further-
more, such data are not new. An excellent
anatomic French study published in the
Journal in 1989 demonstrated that the di-
rect lymphatic drainage of lung segments
to the mediastinal nodes is quite common
for the upper lobes.7 All such reports indi-
cate that isolated involvement of mediasti-
nal sentinel nodes could be considered in
the group of N1 disease. It is not surprising
that a large, cooperative, randomized, pro-
spective trial led to such conclusions.
In conclusion, I think that the current
knowledge on the anatomic pathway of the
pulmonary lymphatic drainage indicates
Tthat the TNM classification regarding N
status is quite rough. The Eastern Cooper-
ative Oncology Group’s trial is another im-
portant confirmation that stage IIIa non–
small cell lung cancer represents an ex-
tremely heterogeneous disease stage, open
to future staging revision.
Francesco Puma, MD,
Chief of General Thoracic Surgery
Azienda Ospedaliera S. Maria
University of Perugia Medical School
Terni, Italy
References
1. Keller SM, Vangel MG, Wagner H, Schiller
JH, Herskovic A, Komaki R, et al. Prolonged
survival in patients with resected non–small
lung cancer and single-level N2 disease.
J Thorac Cardiovasc Surg. 2004;128:130-7.
2. Little AG, DeHoyos A, Kirgan DM, Arcomano
TR, Murray KD. Intraoperative lymphatic map-
ping for non–small cell lung cancer: the sentinel
node technique. J Thorac Cardiovasc Surg.
1999;117:220-4.
3. Liptay MJ, Grondin SC, Fry WA, Pozdol C,
Carson D, Knop C, et al. Intraoperative sen-
tinel lymph node mapping in non-small-cell
lung cancer improves detection of microme-
tastases. J Clin Oncol. 2002:20;1984-8.
4. Nomori H, Horio H, Naruke T, Orikasa H,
Yamazaki K, Suemasu K. Use of technetium-
99m tin colloid for sentinel node identifica-
tion in non–small cell lung cancer. J Thorac
Cardiovasc Surg. 2002;124:486-92.
5. Schmidt FE, Woltering EA, Webb WR,
Garcia OM, Cohen JE, Rozans MH. Sentinel
nodal assessment in patients with carcinoma
of the lung. Ann Thorac Surg. 2002;74:870-5.
6. Sugi K, Kaneda Y, Sudoh M, Sakano H,
Hamano K. Effect of radioisotope sentinel
node mapping in patients with cT1 N0 M0
lung cancer. J Thorac Cardiovasc Surg.
2003;126:568-73.
7. Riquet M, Hidden G, Debesse B. Direct lym-
phatic drainage of lung segments to the me-
diastinal nodes: an anatomic study on 260
adults. J Thorac Cardiovasc Surg. 1989;97:
623-32.
doi:10.1016/j.jtcvs.2004.08.029
Studies of fetal cardiac bypass
To the Editor:
In their elegant studies of fetal cardiopul-
monary bypass (CPB), Carotti and col-
leagues1 use time-dated pregnant sheep of
120 to 130 days’ gestation. Indeed, in all
published studies, the preferred animals for
studying fetal CPB have been near-term
fetal sheep (mean, approximately 126
days’ gestation; term, 148 days’ gestation).
However, this age does not agree with the
now-accepted window for effective fetal
therapy in the clinical setting: 21 to 29
he Journal of Thoracic and Cardiovascularweeks’ human gestation. Therefore we pro-
pose that all investigators conduct future
fetal CPB studies at clinically relevant ges-
tational ages (83-112 days’ gestation in
sheep; see below).
This is of great import when consider-
ing the vast changes taking place in the
uteroplacental and umbilical-placental vas-
cular beds during pregnancy. For example,
the uterine weight, uterine blood flow
(UBF), and UBF per gram of uterine
weight increase significantly from 90 days
onward. Indeed, this final phase in the
growth of UBF is exponential and associ-
ated with a 3-fold increase in fetal weight
that occurs after 110 days in sheep and
beyond 30 weeks in human subjects.2 Sim-
ilarly, blood flow distribution during this
period changes substantially; nearly half
the UBF is diverted away from endometri-
um-myometrium to the placenta. These
changes reflect significant alterations in
placental vascular resistance, which affect
studies of fetal CPB. Finally, similar ges-
tational differences in physiology affect
other experimental features, such as fetal
responses to steroids.3
We would like to caution investigators,
however, against using direct gestational
equivalence (human 280 days  sheep 148
days). Differences in fetal growth rates be-
tween species can lead to large errors when
assuming direct equivalence, as we discov-
ered during our research involving early-
gestation lambs. Therefore, we developed
an equation to successfully translate gesta-
tional equivalence between species on the
basis of previous studies of sheep4 and
human5 embryos that have established the
gestational age for completion of specific
Carnegie stages of development. We trans-
lated these stages into developmental
equivalence at specific times during gesta-
tion. Using the age for each species at
equivalent Carnegie stages and assuming
full-term pregnancy, we derived a second-
degree polynomial equation:
Sheep gestation day   0.003  Human
gestation day2  0.6296  Human gesta-
tion day,
with a correlation coefficient (R2) equal to
0.9973.
Comparing our developmentally based
gestational age with that determined by di-
rect equivalence reveals a difference as
large as 14%, which can significantly affect
experimental design. For example, a 5-day
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Letters to the Editordifference in gestational age (eg, 78 vs 83
days for 21 weeks’ human gestation) can
lead to a difference of 180 g for a singleton
fetus (720 vs 900 g). These weight differ-
ences can have substantial implications in
surgical technique. At the latter part of the
range (29 weeks’ human gestation), when
the fetus is growing more rapidly, the dif-
ference is even larger; for a 107-day (2.23
kg) versus 112-day (2.71 kg) singleton fe-
tus, the difference is about 500 g. Finally,
calculations based on these variations can
also greatly influence results. For example,
calculation of satisfactory fetal CPB flow
rates (on the basis of milliliters per kilo-
gram per hour) can be substantially differ-
ent and potentially inadequate when using
the wrong gestational age and fetal weight.
Joseph A. Sedgwick, MD
Pirooz Eghtesady, MD, PhD
Department of Cardiothoracic Surgery
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH 45244
Department of Surgery
University of Cincinnati
Cincinnati, OH 45221
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Reply to the Editor:
We appreciate the comments of Drs Sedg-
wick and Eghtesady.
Indeed, the increase in uteroplacental
blood flow during the course of pregnancy
initially reflects placental development and
thereafter vasodilation of the spiral arteries,
which increases perfusion of the intravil-
lous space. The increase in uterine blood
flow after 110 days in sheep (75% of the
236 The Journal of Thoracic and Cardiovagestation), which is associated with a
3-fold increase in fetal weight, is related to
vasodilation of the spiral arteries and has
been shown to be proportionate to the in-
crease in wet weight of the uterus and its
metabolically active tissues, including the
fetus, the membranes, and the placenta.1
When performing experiments, investi-
gators should always try to choose experi-
mental settings that are the closest to the
human model that they are trying to repro-
duce, bearing in mind, however, that no
model will ever correspond exactly to the
human condition. This is particularly true
when the experimental setting involves
pregnancies, which depend on a wide num-
ber of factors, including genetic, hormonal,
and anatomic factors, both on the maternal
and fetal side. As such, we welcome the
formula proposed by Drs Sedgwick and
Eghtesady but would caution against a
rigid application.
Uterine blood flow, for example, has
probably little effect in fetal cardiac bypass
experiments because the pump provides
perfusion only to the fetoplacental unit and
not to the maternal uteroplacental compart-
ment. Therefore, endometrial-myometrial
blood flow changes beyond 110 days of
pregnancy are not likely to significantly
influence fetal cardiac bypass.
The increase in fetoplacental blood flow
during the last third of pregnancy reflects
primarily vascular growth and, to a lesser
extent, vasodilation. This generates a fairly
stable fetal umbilical blood flow by the end
of pregnancy of approximately 200 mL ·
kg1 · min1 in most studied species. On
the other hand, placental weight during
ovine pregnancy is relatively stable after
the middle third of gestation.2 Taken to-
gether, these observations indicate that the
increase in fetoplacental blood flow during
the last third of the gestation is proportion-
ate to the increase of the fetal weight.
Therefore, planning of the pump perfusion
rate on the basis of the fetal weight as
predicted by fetal biometry3 at 300 mL ·
kg1 · min1 (100 mL · kg1 · min1 fetal
perfusion rate  200 mL · kg1 · min1
placental perfusion rate) is likely to be ap-
propriate during both the middle and the
last third of the pregnancy.
Beyond all these considerations, our
choice of using near-term fetal sheep orig-
inated primarily from the general consen-
sus in the literature of using animals at this
stage of pregnancy, which also allows us to
scular Surgery ● January 2005perform operations on larger fetuses. The
suggestion of lowering the gestational age
of future fetal experiments at 83 to 112
days of pregnancy in sheep is well ac-
cepted, but its benefits will need to be
proved experimentally.
Adriano Carotti, MDa
Francesco Emma, MDb
Department of Pediatric Cardiology and
Cardiac Surgerya
Department of Nephrology and Dialysisb
Ospedale Bambino Gesú
Rome, Italy
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Separate or composite graft
replacement for diseases of both the
aortic valve and the ascending aorta
To the Editor:
With great interest, we read an excellent
article entitled “Clinical outcomes after
separate and composite replacement of the
aortic valve and ascending aorta,” in the
August 2004 issue of the Journal.1 Sioris
and associates reported the differences be-
tween aortic root replacement and aortic
valve replacement combined with supra-
coronary replacement of the ascending
aorta (separate grafting). They concluded
that separate grafting and the Bentall oper-
ation provide comparable long-term results
and that no patient required reoperation for
aortic root aneurysm after separate grafting
in patients with aortic valve disease asso-
ciated with normal or mildly dilated aortic
sinuses or a dilated ascending aorta. Their
study consisted of a large number of
patients (587 patients), and their mean
follow-up was 4.6  3.1 years.
We have a patient who required aortic
root replacement because of dilatation of
the residual sinuses of Valsalva 10 years
after separate grafting.2 The patient had
undergone the initial operation for type A
